Experimental Drug Improves Pancreatic Cancer Survival in Clinical Trial

A Phase 3 clinical trial for the experimental drug daraxonrasib demonstrated improved survival rates for pancreatic cancer patients previously treated with chemotherapy. The drug reduced the overall risk of death by 60% compared to standard chemotherapy in advanced pancreatic cancer cases. Participants receiving daraxonrasib showed an average survival of 13 months, versus 6 months for those on standard chemotherapy.

Tumor shrinkage or disappearance was observed in approximately 31% of daraxonrasib recipients, compared to 11% in the chemotherapy group. Specifically, for patients with the G12 RAS mutation, tumor control lasted a median of 7 months with daraxonrasib versus 3 months with chemotherapy.

Side effects were reported in 96% of participants

Side effects were reported in 96% of participants receiving daraxonrasib, with approximately one-third experiencing Grade 3 or higher adverse events. These included rash, diarrhea, nausea, stomatitis, mucositis, vomiting, and fatigue.

Concerns regarding the drug's accessibility, dependent on cost and insurance coverage, have been raised. The drug targets activating RAS mutations, present in 92% of pancreatic cancer cases.